PTC Therapeutics, Inc. filed a Form 8-K on October 29, 2026, announcing financial results for the quarter ended September 30, 2026, and disclosing an updated corporate presentation under Regulation FD.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Press release: A press release dated October 29, 2026, was furnished as Exhibit 99.1 to the filing.
  • Conference call: The company disclosed it would host a conference call on October 29, 2026, at 4:30 p.m. eastern time to review quarterly results and other corporate highlights.
  • Corporate presentation: An updated corporate presentation dated October 2026 was furnished as Exhibit 99.2 and posted to the company's investor relations website.
  • Signatory: The filing was signed by Pierre Gravier, Chief Financial Officer, on October 29, 2026.

PTC Therapeutics Announces Q3 2026 Earnings and Regulation FD Update

According to the filing, PTC Therapeutics, Inc. (NASDAQ:PTCT), headquartered at 500 Warren Corporate Center Drive, Warren, NJ, submitted a Current Report on Form 8-K on October 29, 2026. The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), covering the company's third-quarter performance for the period ended September 30, 2026.

The company disclosed that a press release containing the full text of the financial results announcement was furnished as Exhibit 99.1. Per the filing, the company also planned a conference call the same day at 4:30 p.m. eastern time, during which management expected to "review financial results for the quarter ended September 30, 2026, as well as other corporate highlights and updates." Access instructions for the call were included in the press release.

In connection with the Regulation FD disclosure under Item 7.01, the company reported that it updated its corporate presentation as of October 29, 2026. The presentation was attached as Exhibit 99.2 and was also made available on the Events and Presentations page of the company's investor relations website. The filing notes that the information furnished under Items 2.02 and 7.01, including both exhibits, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings except as expressly specified.

What Was Disclosed

PTC Therapeutics filed an 8-K on October 29, 2026, furnishing its Q3 2026 press release and an updated corporate presentation, and announcing a same-day earnings conference call at 4:30 p.m. eastern time. The filing was signed by CFO Pierre Gravier.